FindTrial
Sign In

Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration - ND

Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-004320-36-IT
Enrollment
Unknown
Registered
2007-05-03
Start date
2006-07-25
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Viasual acuity loss MedDRA version: 9.1 Level: SOC Classification code 10015919 Term: Eye disorders

Interventions

Product Name: BEVACIZUMAB Pharmaceutical Form: Solution for injection INN or Proposed INN: BEVACIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade N

Sponsors

AZIENDA OSPEDALIERA SENESE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - neovascular age-related macular degeneration - age > 55 - Visual loss =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - previous ocular infections - intravitreal hemoragies

Design outcomes

Primary

MeasureTime frame
Main Objective: Viasual acuity loss prevention in patients with age-related macular degeneration vs standard therapy;Secondary Objective: - Improvement in visual acuity, OCT and angiographic outcomes;Primary end point(s): Viasual acuity loss prevention in patients with age-related macular degeneration vs standard therapy—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026